Brainsonix Pulsar 1002 for Attention Deficit Hyperactivity Disorder (ADHD)

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Attention Deficit Hyperactivity Disorder (ADHD)Brainsonix Pulsar 1002 - Device
Eligibility
18 - 60
All Sexes
What conditions do you have?
Select

Study Summary

This trial will study the long-term effects of transcranial ultrasound on people with ADHD.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

Study Objectives

0 Primary · 1 Secondary · Reporting Duration: Post Final Treatment (8 weeks from baseline)

Week 8
Adult ADHD Self-Report Scale (ASRS-v1.1)

Trial Safety

Safety Progress

1 of 3

Similar Trials

Trial Design

1 Treatment Group

Focused Ultrasound
1 of 1

Experimental Treatment

100 Total Participants · 1 Treatment Group

Primary Treatment: Brainsonix Pulsar 1002 · No Placebo Group · N/A

Focused Ultrasound
Device
Experimental Group · 1 Intervention: Brainsonix Pulsar 1002 · Intervention Types: Device

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: post final treatment (8 weeks from baseline)

Who is running the clinical trial?

Neurological Associates of West Los AngelesLead Sponsor
24 Previous Clinical Trials
3,855 Total Patients Enrolled
Sheldon Jordan, MDPrincipal InvestigatorNeurological Associates of West Los Angeles
12 Previous Clinical Trials
2,490 Total Patients Enrolled

Eligibility Criteria

Age 18 - 60 · All Participants · 4 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
The person's score on the Adult ADHD Self-Report Questionnaire (ASRS-V1.1) was 8 or higher, indicating that they have symptoms of ADHD.
The most common symptoms of ADHD are hyperactivity, impulsiveness, and inattention
with a remission of symptoms may warrant a change in treatment plan
You must be at least 18 years old to use this product.

Who else is applying?

What state do they live in?
California66.7%
Illinois33.3%
How old are they?
18 - 65100.0%
What site did they apply to?
Neurological Associates of West LA75.0%
Neurological Associates of West Los Angele25.0%
What portion of applicants met pre-screening criteria?
Met criteria80.0%
Did not meet criteria20.0%
References